COMMUNIQUÉS West-GlobeNewswire

ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value
05/01/2026
UNIONDALE, NY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. ( OTC: PRPH ) today provided an update to shareholders regarding recent trading activity, its capital structure, and the Company’s underlying asset [...]
Communiqué de presse : Le médicament Tzield de Sanofi a été accepté pour un examen prioritaire aux États-Unis pour les jeunes enfants atteints de diabète de type 1 de stade 2
05/01/2026
Le médicament Tzield de Sanofi a été accepté pour un examen prioritaire aux États-Unis pour les jeunes enfants atteints de diabète de type 1 de stade 2 Si elle est approuvée, Tzield serait la première thérapie modifiant [...]
Press Release: Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes
05/01/2026
Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-modifying therapy to delay the onset of stage 3 T1D in children aged [...]
argenx Announces Leadership Transition Marking Next Evolution of Growth
05/01/2026
Tim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO to CEO and Executive Director January 5, 2026 7:00 a.m. CET Amsterdam, the [...]
Idorsia’s JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension
05/01/2026
Idorsia receives approval from Health Canada for JERAYGO ™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension. JERAYGO is a new oral antihypertensive [...]
Burning Rock Announces Founder’s Purchase of Its ADSs
05/01/2026
GUANGZHOU, China, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in [...]
Nicox annonce le remboursement intégral de sa dette avec Kreos Capital et étend son horizon de trésorerie au-delà de 2027 grâce à un nouveau financement complémentaire
05/01/2026
Communiqué de presse Nicox annonce le remboursement intégral de sa dette avec Kreos Capital et étend son horizon de trésorerie au-delà de 2027 grâce à un nouveau financement complémentaire La position de la Société sort [...]
Nicox Announces Complete Repayment of Kreos Capital Debt and Extends Cash Runway Beyond 2027 with New Additional Financing
05/01/2026
Press Release Nicox Announces Complete Repayment of Kreos Capital Debt and Extends Cash Runway Beyond 2027 with New Additional Financing Company’s position strengthened, enabling flexibility in strategic discussions All [...]
TME PHARMA FAIT LE POINT SUR SES ACTIVITÉS
05/01/2026
TME PHARMA FAIT LE POINT SUR SES ACTIVITÉS Berlin, Allemagne, 5 janvier 2025, 8 h 00 CET – TME Pharma N.V. (Euronext Growth Paris : ALTME), une société de biotechnologie au stade clinique spécialisée dans le [...]
TME Pharma provides update on its activities
05/01/2026
TME Pharma provides update on its activities Berlin, Germany , January 5, 2025, 08.00 CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel [...]
HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma
05/01/2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase III part of the Phase [...]
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
04/01/2026
SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide [...]
Best Over The counter Sleep Aid 2026: Launched By NooCube Strongest natural sleep aid, Pills For Sleep And Anxiety Without Side effects
04/01/2026
Strongest sleep aid over the counter sleep Pills NooCube best for sleep and anxiety read side effects, benefits, ingredients of NooCube supplement New York City, Jan. 04, 2026 (GLOBE NEWSWIRE) -- In 2026 Getting good [...]
Best Male Enhancement Pills 2026: Launched By Performer 8' Over The Counter ED Pills For Erectile Dysfunction, Growth & Last Longer for Men
04/01/2026
best male enhancement pills sold in stores' Pills for Erectile dysfunction for men, Effective Formula for last longer and testosterones booster Quality Criteria Examined in New Industry Analysis New York City,, Jan. 04 [...]
CystoSmart™, an AI Software Tool for Bladder Cancer Detection, Developed with Cutting-Edge Technology Receives Clearance from Health Sciences Authority Singapore
04/01/2026
SINGAPORE and LONDON and NEW YORK, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Intelligent Scopes Corp (“ISC”), specializing in state-of-the-art image enhancement and precision AI software solutions for urology and [...]
CJC 1295 Ipamorelin Unveiled 2026: Examining the Science Behind CJC-1295 Peptides and Growth Hormone Stack for Muscle Growth By CrazyBulk
04/01/2026
Discover how CJC-1295 peptide stack research has influenced CrazyBulk’s Growth Hormone Stack, designed to support recovery speed, lean muscle, and training output. Intro New York City, NY, Jan. 04, 2026 (GLOBE NEWSWIRE [...]
Best Chocolate Weight Loss Supplement: Consumer Analysis Examines Cacao GLP-1 Research as January Wellness Interest Surges
03/01/2026
Consumer analysis evaluates Earth Echo Cacao Bliss ingredient disclosures, ceremonial-grade processing claims, and published GLP-1 research frequently referenced in chocolate-based weight management supplement [...]
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/01/2026
CAMBRIDGE, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today [...]
GH Research to Announce IND Status for GH001
02/01/2026
DUBLIN, Jan. 02, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in [...]

Pages